camcevi
Search...
Search...

This site is intended for use by U.S. residents only.

©2024 CAMCEVI. All rights reserved. WS-CAM-2200006

ABOUT CAMCEVI

GnRH AGONIST HORMONE-BLOCKING THERAPY

GnRH stands for gonadotropin-releasing hormone. It’s a type of medicine that stops the testicles from making sex hormones.1

GnRH stands for gonadotropin-releasing hormone. It’s a type of medicine that stops the testicles from making the sex hormones, testosterone.1

Why lower your testosterone (T) levels?

Testosterone is the main hormone, or androgen, in men. It is this hormone that “feeds” prostate cancer and allows it to grow. Hormone-blocking therapies are designed to stop your body from making testosterone so it can’t feed the cancer.2

How it works

1

Testosterone feeds
cancer cells

ICON - TESTOSTERONE FEEDS CANCER CELLS

Most of a man’s testosterone is made in the testicles. Testosterone encourages the growth of prostate cancer cells.

2

CAMCEVI® stops testosterone production at the source

ICON - CAMCEVI STOPS TESTOSTERONE PRODUCTION AT THE SOURCE

CAMCEVI prevents the testicles from making testosterone. This makes it harder for the tumor to grow.

3

Testosterone
levels drop3

ICON - TESTOSTERONE LEVELS DROP

In about 4 weeks, your testosterone levels are expected to drop to very low levels.3 Your healthcare professional will monitor your testosterone levels to know how well CAMCEVI is working.

NOTE: After a first injection of CAMCEVI, testosterone levels may go up for a short while.3 This is known as a flare, and it is common. Your healthcare professional will monitor you throughout treatment to know how well CAMCEVI is working.

Once testosterone levels are reduced, studies show they stay low for 6 months.3 Then it’s time for another CAMCEVI treatment.

1

Testosterone feeds
cancer cells

plus
ICON - TESTOSTERONE FEEDS CANCER CELLS

Most of a man’s testosterone is made in the testicles. Testosterone encourages the growth of prostate cancer cells.

2

CAMCEVI® stops testosterone production at the source

plus
ICON - CAMCEVI STOPS TESTOSTERONE PRODUCTION AT THE SOURCE

CAMCEVI prevents the testicles from making testosterone. This makes it harder for the tumor to grow.

3

Testosterone
levels drop3

plus
ICON - TESTOSTERONE LEVELS DROP

In about 4 weeks, your testosterone levels are expected to drop to very low levels.3 Your healthcare professional will monitor your testosterone levels to know how well CAMCEVI is working.

NOTE: After a first injection of CAMCEVI, testosterone levels may go up for a short while.3 This is known as a flare, and it is common. Your healthcare professional will monitor you throughout treatment to know how well CAMCEVI is working.

Once testosterone levels are reduced, studies show they stay low for 6 months.3 Then it’s time for another CAMCEVI treatment.

Understanding side effects

Side effects can be common with hormone-blocking therapies like CAMCEVI. It’s important to know what the common side
effects of CAMCEVI are, so you can talk to your healthcare professional about them. These include:

  • Hot flash3
  • High blood pressure3
  • Reaction where you received your shot, which may cause temporary burning/stinging, pain, bruising, or redness3
  • Upper respiratory tract infections3
  • Muscle and bone pain3
  • Tiredness3
  • Tiredness, also known as fatigue3
  • Pain in extremity, such as the neck, shoulders, arms, and legs3

This is not all of the important safety information for CAMCEVI. Review the complete Important Safety Information by clicking on the + icon at the bottom of the screen.

You may experience other side effects and should always tell your healthcare professional about how you are feeling when receiving CAMCEVI.

Call your healthcare professional for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088 or fda.gov/medwatch.

IMPORTANT SAFETY INFORMATION

What is CAMCEVI®? CAMCEVI is an androgen deprivation therapy (ADT) used for treatment of adult patients with advanced prostate cancer.

You should not take CAMCEVI if you have ever had an allergic reaction to any of the ingredients in CAMCEVI or to any other medications called gonadotropin-releasing hormone (GnRH) agonists.

CAMCEVI may:

Cause an increase in your testosterone level during the initial few weeks of treatment, which may cause temporary worsening of symptoms or additional signs and symptoms of prostate cancer. You may experience a temporary increase in bone pain. You may have trouble with urination or develop abnormal amount of pressure on your spinal cord which can result in paralysis, which may be life-threatening.

Cause your blood sugar to increase, including increasing your risk of developing diabetes. You should have your blood sugar monitored while taking CAMCEVI.

Increase your risk of heart problems including heart attack, sudden death, or stroke. It can also cause your heart to beat irregularly.

Cause some patients to have seizures.

Cause fetal harm if administered to a pregnant woman.

Cause impotence and impair fertility in males of reproductive potential.

The most common side effects of CAMCEVI include hot flush, high blood pressure, reaction where you received your shot which may cause temporary burning/stinging, pain, bruising or redness, upper respiratory tract infections, muscle and bone pain, tiredness, and pain in extremities. Tell your healthcare provider if you experience a rash or severe injection site reaction.

For more information, talk to your healthcare provider.

These are not all the possible side effects of CAMCEVI. For additional information, see the full prescribing information or ask your healthcare professional or pharmacist.

You are encouraged to report negative side effects of prescription drugs to the FDA at 1-800-FDA-1088 or visit
www.fda.gov/medwatch.

Click here for full Prescribing Information.

References:

1. National Cancer Institute. NCI Dictionaries. GnRH Agonist. Accessed January 19, 2022. https://www.cancer.gov/publications/dictionaries/.cancer-terms/def/gnrh-agonist 2. NCCN Guidelines for Patients. Prostate Cancer Advanced Stage, 2020. Published 2020. Accessed January 19, 2022. https://www.nccn.org/ patients/guidelines/content/PDF/prostate-advanced-patient.pdf 3. CAMCEVI. Prescribing information. Accord BioPharma; May 2021.